Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | RARG | P13631 | 7/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | RARA | P10276 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505088 | 0.90 | GAA (0.56) | GAATSHRMRGPRX4KDM4ELMNA | |
| SCHEMBL13419790 | 0.89 | RARG (0.52) | GAATSHRRARGMRGPRX4KDM4E | |
| SCHEMBL1505166 | 0.88 | GAA (0.60) | GAATSHRMRGPRX4KDM4ELMNA | |
| SCHEMBL13419786 | 0.84 | PTGDR2 (0.50) | TSHRRARGKDM4ERARARARB | |
| SCHEMBL31037191 | 0.84 | RARG (0.48) | TSHRRARGRARARARBALDH1A1 | |
| SCHEMBL1505156 | 0.80 | GAA (0.57) | GAATSHRMRGPRX4KDM4EALDH1A1 | |
| SCHEMBL8945690 | 0.80 | ALDH1A1 (0.66) | TSHRRARGKDM4ELMNAALDH1A1 | |
| SCHEMBL8399454 | 0.80 | KDM4E (0.52) | GAAKDM4ELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL1505183 | 0.79 | GAA (0.56) | GAATSHRMRGPRX4KDM4ELMNA | |
| SCHEMBL20522075 | 0.78 | GAA (0.61) | GAATSHRMRGPRX4LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | STAT6, RELA, NFKB2 | GAA 3412/4885TSHR 1508/4885RARG 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.